NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, today announced that its Chief Scientist and co-founder, Anatole Klyosov, Ph.D., published articles in: the Biochemical Journal, Carbohydrate Research and Glycobiology that further define the mechanism of action of its lead compound DAVANAT® and the role it plays in the treatment of cancer.
